FDA Brief

Warning letters Drugs

FDA warning letter to

Laboratorios Jaloma S.A. de C.V.

High riskIssued Jan 25, 2021Posted Jan 26, 2021Center for Drug Evaluation and Research | CDER

Laboratorios Jaloma's hand sanitizer labeled 62% ethanol contained 32% methanol and was refused at U.S. border.

What happened

FDA tested a batch of Jaloma Antiseptic Hand Sanitizer that was detained and refused admission at the U.S. border. The product was labeled to contain 62% ethanol, but FDA found on average 32% ethanol and 32% methanol. FDA held a July 22, 2020 teleconference with the firm, and the firm recalled the product on July 31, 2020.

What FDA found

  1. FDA found the hand sanitizer contained about 32% methanol instead of the labeled 62% ethanol, so the active ingredient was substituted.

    section 501(d)(2) of the FD&C Act, 21 U.S.C. 351(d)(2)
  2. The methanol substitution shows the facility's quality assurance was not working under CGMP (current good manufacturing practice).

    section 501(a)(2)(B), 21 U.S.C. 351(a)(2)(B)
  3. The hand sanitizer is an unapproved new drug because it is not generally recognized as safe and effective and has no FDA approval.

    section 505(a), 21 U.S.C. 355(a)
  4. The product is dangerous to health when used as labeled because it contains methanol.

    section 502(j), 21 U.S.C. 352(j)
  5. The label falsely says 62% ethanol and omits methanol, making the labeling false and misleading.

    sections 502(a) and 502(e)(1)(A), 21 U.S.C. 352(a), 352(e)(1)(A)
  6. The product does not meet the requirements for marketing as a nonprescription drug under section 505G.

    section 502(ee), 21 U.S.C. 352(ee)

What FDA wants

FDA asks the firm to respond in writing within 15 working days with a detailed investigation, raw material and supplier lists, U.S. shipment and reconciliation records, batch records, and analytical test results, and to consider a qualified CGMP consultant. If corrections cannot be completed in time, the firm must explain the delay and give a completion schedule.

Who should pay attention

  • brands and distributors that buy hand sanitizer from this manufacturer
  • U.S. importers and retailers selling consumer hand sanitizers
  • quality teams at drug contract manufacturers and repackagers

This is a summary. Read the original letter on fda.gov.

Laboratorios Jaloma S.A. de C.V.'s FDA history

  1. Laboratorios Jaloma S.A. de C.V.

    FDA found Laboratorios Jaloma’s OTC drug lab records were inaccurate, microbial tests unvalidated, and electronic data missing or uncontrolled.

    High risk

Full company page

Similar letters to other companies

  1. World Perfumes Inc.

    World Perfumes failed to test drug ingredients for toxic contaminants and had inadequate water, FDA says.

    High risk
  2. RNA Bio/Pharma, Incorporated

    FDA found RNA Bio/Pharma failed to test homeopathic oral liquid drugs for dangerous contaminants and did not validate its water system.

    High risk
  3. Kabana Skin Care LLC

    Kabana Skin Care failed to test OTC drug ingredients and finished products, prompting a recall and halt of U.S. drug manufacturing.

    High risk
  4. Ningbo Riway Industrial Co., Ltd.

    Ningbo Riway Industrial, an OTC drug maker in China, was cited for manufacturing-practice failures and unapproved antiseptic wipes.

    High risk